RESUMO
INTRODUCTION: Coronary artery stent infection is a rare event. We report a case of delayed coronary artery stent infection with coronary cameral fistula presented as pyrexia of unknown origin, 1 year after coronary intervention. CASE PRESENTATION: A 66-year-old man presented with paroxysmal low-grade fever of 2 years duration. He underwent percutaneous coronary intervention (PCI) with stent to right coronary artery (RCA) for inferior wall myocardial infarction in July 2014. He had non-ST-elevation myocardial infarction in December 2014. Repeat PCI with two stents to same vessel was done for total occlusion of stent. Repeated evaluations by family physician for fever did not yield any discrete diagnosis, and he was treated with empirical antibiotics. He had worsening of fever since last 2 months. Whole body positron emission tomography scan showed increased tracer uptake in RCA with perivascular abscess involving lateral wall of right ventricle. Coronary angiogram showed presence of small coronary cameral fistula from RCA draining into right atrium. Blood cultures grew Pseudomonas aeruginosa. He was taken for surgery and the infected portion of the RCA including the stents was removed. DISCUSSION: This case reports delayed coronary stent infection. Patient presented 1 year after procedure. Presence of bare metal stent increases risk of infection in presence of bacteraemia. Antiproliferative effects of drug eluting stents may predispose more to infection. This case was unique in its late presentation, presence of coronary cameral fistula and was successfully treated with surgery.
RESUMO
BACKGROUND: Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated. METHODS: Patients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed. RESULTS: At month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score. CONCLUSIONS: Macitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00660179; URL: clinicaltrials.gov.
